About
Profile
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
OMER
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Omeros Non-GAAP EPS of -$0.37 misses by $0.31
- Omeros Q4 2021 Earnings Preview
- Omeros responds to Complete Response Letter on narsoplimab for kidney damage
- Omeros could trade as a pure-play biotech after divesting Omidria - Cantor
- ICE Biotech index rejig: AUPH, AVXL among added; AMRS, GH among deleted
- Omeros to sell OMIDRIA franchise to Rayner Surgical for more than $1B
- Top 10 deletions from the MSCI US Investable Market 2500 Index during semi-annual rejig
- Omeros EPS beats by $0.01, beats on revenue
- Omeros Q3 2021 Earnings Preview
- Omeros' long term data of phase 2 trial of narsoplimab shows benefit in kidney disorder
- Valneva SE, MeiraGTx leads healthcare gainers; Revance Therapeutics, Omeros aming major losers
- Omeros shares slide 18% after FDA fails to approve narsoplimab treatment
- Hot Stocks: F, TTM deal rumors; TTWO release; RPTX clarifies data; OMER downgrade; IMOS misses revenue
- Omeros' rough start to October continues as shares down ~24%
- Omeros slips 11% on JPMorgan downgrade, analyst anticipates CRL
- Omeros continues decline on deficiencies with narsoplimab BLA, analyst downgrades
- Xenon Pharmaceuticals, Milestone Scientific leads healthcare gainers; Owlet, REGENXBIO among major losers
- Atea Pharma, Evolent among weekly healthcare gainers; Omeros, Novavax trail
- Progenity, Biomerica leads healthcare gainers; Omeros, Adagio Therapeutics among major losers
- Omeros suffers setback in U.S. marketing application for narsoplimab
Date | Price | Open | High | Low | Vol | ER | |||
---|---|---|---|---|---|---|---|---|---|
Sep 2 | 4.51 | 4.40 |
4.72
|
4.20
|
668.15K | ||||
Sep 1 | 4.36 | 3.95 |
4.36
|
3.80
|
472.75K | ||||
Aug 31 | 4.03 | 3.70 |
4.12
|
3.70
|
341.02K | ||||
Aug 30 | 3.73 | 3.75 |
3.87
|
3.66
|
320.10K | ||||
Aug 29 | 3.76 | 3.75 |
3.94
|
3.71
|
466.72K | ||||
Aug 26 | 3.82 | 3.96 |
4.04
|
3.79
|
532.88K | ||||
Aug 25 | 3.93 | 4.40 |
4.41
|
3.87
|
870.88K | ||||
Aug 24 | 4.32 | 4.80 |
4.91
|
4.31
|
801.16K | ||||
Aug 23 | 4.79 | 5.17 |
5.37
|
4.78
|
865.01K | ||||
Aug 22 | 5.13 | 5.69 |
5.87
|
5.09
|
921.84K | ||||
Aug 19 | 5.87 | 5.96 |
6.15
|
5.80
|
420.95K |